PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64
Clinical trial NCT04765436 · COMPLETED
Trial details
- NCT number
- NCT04765436
- Sponsor
- Providence Therapeutics Holdings Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-14
- Primary completion
- 2022-03-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.